Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk to invest $1.09 billion to increase production in Brazil
Novo Nordisk , the producer of Ozempic and other medications, announced on Monday a 6.4 billion reais ($1.09 billion) investment in Brazil to boost production.
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Novo Nordisk's head of commercial strategy steps down
Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.
Coffers swelling on Wegovy sales, Novo Holdings doubles income and returns in 2024
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on Wednesday.
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case for NVO, why their addressed market and market position are still looking phenomenal. I look at fundamental valuation and technical analysis.
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term.
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four years on average in patients with diabetes and established heart disease, with or without chronic kidney disease.
1 no-brainer biotech giant to buy in April
The advent of weight-loss drugs, primarily semaglutide, proved to be an immense boon for biotech giants — primarily Novo Nordisk and Eli Lilly.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk says compounded drugs are hurting Wegovy sales
CNBC's Karen Gilchrist discusses the impact of U.S. compounded weight loss drugs and potential tariffs on obesity drug giant Novo Nordisk.
